|Bid||131.03 x 800|
|Ask||131.27 x 800|
|Day's range||128.50 - 131.87|
|52-week range||117.08 - 189.07|
|Beta (5Y monthly)||0.24|
|PE ratio (TTM)||3.18|
|Earnings date||27 Mar 2023|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||02 June 2022|
|1y target est||216.40|
BioNTech to receive exclusive worldwide license from OncoC4 to develop and commercialize its anti-CTLA-4 monoclonal antibody candidate, ONC-392BioNTech and OncoC4 will co-develop ONC-392 as monotherapy or in combination with anti-PD1 in various solid tumor indications, with a randomized Phase 3 trial planned to start in 2023BioNTech also plans to combine ONC-392 with its proprietary oncology product candidates to evaluate complementary modes of action with the aim to increase therapeutic effect
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Pfizer (PFE) and partner BioNTech receive FDA label expansion to use their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine as a single booster dose in young children under five years.